[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Amant F, Van Calsteren K, Debiec-Rychter M, Heyns L, De Beeck KO, Sagaert X, Bollen B, Vergote I: High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case report. J Med Case Rep; 2010;4:243
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade endometrial stromal sarcoma presenting in a 28-year-old woman during pregnancy: a case report.
  • INTRODUCTION: To the best of our knowledge, soft tissue sarcomas have not prevously been reported as a complication during pregnancy.
  • CASE PRESENTATION: A 28-year-old Caucasian woman was diagnosed with a transperitoneal sarcoma during pregnancy.
  • Morphological, immunohistochemical, chromosomal and mutational analyses pointed towards a high-grade endometrial stromal sarcoma.
  • Although surgery and chemotherapy are possible during pregnancy, we were unable to perform these in this case.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Anat Pathol. 2000 Sep;7(5):257-81 [10976906.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Jun 10;108(2):217-22 [12781415.001]
  • [Cites] J Pathol. 2004 Apr;202(4):430-8 [15095270.001]
  • [Cites] Lancet Oncol. 2004 May;5(5):283-91 [15120665.001]
  • [Cites] Surg Endosc. 2004 Sep;18(9):1354-7 [15164277.001]
  • [Cites] Gynecol Oncol. 2004 Nov;95(2):412-3; author reply 413 [15491769.001]
  • [Cites] Am J Surg. 2005 Sep;190(3):467-73 [16105538.001]
  • [Cites] J Clin Anesth. 2006 Feb;18(1):60-6 [16517336.001]
  • [Cites] Gynecol Oncol. 2007 May;105(2):446-50 [17292456.001]
  • [Cites] BMC Pregnancy Childbirth. 2008;8:3 [18205951.001]
  • [Cites] Int J Gynecol Cancer. 2009 May;19 Suppl 1:S1-12 [19509538.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):683-9 [19841323.001]
  • (PMID = 20684773.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2925352
  •  go-up   go-down


2. Paillocher N, Lortholary A, Abadie-Lacourtoisie S, Morand C, Verriele V, Catala L, Descamps P: [Low-grade endometrial stromal sarcoma: contribution of hormone therapy and etoposide]. J Gynecol Obstet Biol Reprod (Paris); 2005 Feb;34(1 Pt 1):41-6
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Low-grade endometrial stromal sarcoma: contribution of hormone therapy and etoposide].
  • [Transliterated title] Sarcome du chorion cytogène de bas grade. Mise au point sur l'intérêt de l'hormonothérapie et de l'étoposide à partir de 4 cas.
  • Endometrial stromal sarcoma is a rare malignant uterine tumor.
  • We report 4 cases of low-grade endometrial stromal sarcoma, corresponding to the form with a mitotic index at less than 10 mitoses per 10 high power fields (HPF), from which we carried out a review of the literature and defined the potential interest of hormone therapy and chemotherapy by etoposide.
  • The initial treatment is mainly based open surgery, generally total hysterectomy with annexectomy.
  • There is no effective adjuvant treatment.
  • The potential of reccurences remains around 50% with a 34-month median.
  • Several therapeutic options are possible after recurrence but no standard treatment has been established.
  • Chemotherapy by oral etoposide offers easy administration, good compliance and acceptable toxicity with median 20-month remission in 3 patients before progression.
  • Hormone therapy with progestogens (hormone receptor expression of the tumor is 71% for estrogens and 95% for progesterone) is widely studied in the literature with a 46% response rate and 46% rate of disease stabilization.
  • Hormone therapy with an anti-aromatase appears to be a promising treatment according to the bibliographic references on this subject.
  • Overall, prognosis of low-grade endometrial sarcoma is relatively good with 100% survival at 5 years.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Endometrial Neoplasms / drug therapy. Etoposide / therapeutic use. Progestins / therapeutic use. Sarcoma / drug therapy

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767916.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Progestins; 6PLQ3CP4P3 / Etoposide
  • [Number-of-references] 23
  •  go-up   go-down


3. Nam EJ, Kim JW, Lee DW, Jang SY, Hong JW, Kim YT, Kim JH, Kim S, Kim SW: Endometrial stromal sarcomas: a retrospective analysis of 28 patients, single center experience for 20 years. Cancer Res Treat; 2008 Mar;40(1):6-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial stromal sarcomas: a retrospective analysis of 28 patients, single center experience for 20 years.
  • PURPOSE: The aim of this study was to evaluate the behavior of endometrial stromal sarcomas (ESSs) in relation to their clinical and pathogenic features, and to determine the optimal treatment strategy.
  • Twenty-two (81.5%) and 5 patients (18.5%) had low- and high-grade disease, respectively.
  • However, among those patients with low-grade tumors, 5/20 patients (25%) had a recurrence and 2/21 patients (9.5%) had distant metastasis during the follow-up period.
  • With the exception of 2 patients, 26 patients with ESSs underwent hysterectomy as primary treatment.
  • Adjuvant treatment after surgery was administered to 14/26 patients (53.8%).
  • Hormone therapy with progesterone, chemotherapy, and/or radiotherapy did not influence overall survival.
  • However, the postoperative adjuvant therapy group, regardless of the treatment modality, was associated with relatively increased overall survival when compared to the surgery only group (p=0.054).
  • We recommend adjuvant therapy be administered after hysterectomy in patients with ESS to prevent recurrence or distant metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2007 Nov 5;97(9):1194-9 [17895898.001]
  • [Cites] Anticancer Drugs. 2000 Apr;11(4):275-8 [10898543.001]
  • [Cites] Gynecol Oncol. 2006 Jun;101(3):464-9 [16368128.001]
  • [Cites] Obstet Gynecol. 2005 Dec;106(6):1304-8 [16319256.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):402-6 [15661228.001]
  • [Cites] Gynecol Oncol. 1997 Feb;64(2):265-9 [9038274.001]
  • [Cites] Gynecol Oncol. 1996 Nov;63(2):247-53 [8910635.001]
  • [Cites] Obstet Gynecol. 1996 May;87(5 Pt 1):747-50 [8677079.001]
  • [Cites] Gynecol Oncol. 1995 Aug;58(2):262-5 [7622117.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1991 Mar 21;39(1):63-9 [2029958.001]
  • [Cites] Gynecol Oncol. 1989 Dec;35(3):290-3 [2689303.001]
  • [Cites] Cancer. 1987 Oct 15;60(8 Suppl):2035-41 [3652025.001]
  • [Cites] Cancer. 1985 Apr 15;55(8):1648-53 [3884128.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):35-9 [2354406.001]
  • [Cites] Am J Surg Pathol. 1990 May;14(5):415-38 [2327549.001]
  • [Cites] Gynecol Oncol. 1990 Jan;36(1):60-5 [2295453.001]
  • [Cites] Gynecol Oncol. 1990 Jan;36(1):113-8 [2295442.001]
  • [Cites] Cancer. 1966 Jun;19(6):755-66 [5939046.001]
  • [Cites] Gynecol Oncol. 2004 Nov;95(2):412-3; author reply 413 [15491769.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Aug 15;109(2):209-13 [12860344.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):170-6 [12821359.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):160-5 [11330943.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):739-48 [11172957.001]
  • [Cites] Eur Radiol. 2001;11(1):28-33 [11194912.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):630-4 [17320937.001]
  • (PMID = 19688058.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2699082
  • [Keywords] NOTNLM ; Chemotherapy / Endometrial / Radiotherapy / Sarcoma / Stromal / Treatment outcome
  •  go-up   go-down


Advertisement
4. Saga Y, Ohwada M, Kohno T, Takayashiki N, Suzuki M: High-grade endometrial stromal sarcoma after treatment with tamoxifen in a patient treated for breast cancer. Int J Gynecol Cancer; 2003 Sep-Oct;13(5):690-2
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade endometrial stromal sarcoma after treatment with tamoxifen in a patient treated for breast cancer.
  • Tamoxifen has been widely used in breast cancer treatment.
  • In recent years, the occurrence of uterine malignancies in patients receiving long-term tamoxifen therapy has attracted attention.
  • Most of these malignancies are endometrial adenocarcinomas, but low-grade endometrial stromal sarcomas have occasionally been reported.
  • Here we report a woman who developed a high-grade endometrial stromal sarcoma after receiving postmastectomy tamoxifen therapy.
  • At age 51, she was diagnosed with endometrial stromal sarcoma, for which a radical hysterectomy was performed.
  • High-grade endometrial stromal sarcoma was diagnosed by postoperative histologic examination.
  • Immunostaining for the estrogen receptor was negative in sarcoma cells, but positive in the residual endometrial epithelium and the nucleus of adjacent stromal cells within the tumor.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Endometrial Neoplasms / diagnosis. Sarcoma, Endometrial Stromal / diagnosis. Tamoxifen / adverse effects

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14675357.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


5. Ushijima M, Yamakawa Y, Sakabe E, Waki H, Katou K: [A case of recurrent high-grade endometrial stromal sarcoma controlled by a combination of Ifosfamide, adriamycin, and cisplatin]. Gan To Kagaku Ryoho; 2010 Oct;37(10):2003-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent high-grade endometrial stromal sarcoma controlled by a combination of Ifosfamide, adriamycin, and cisplatin].
  • A 52-year-old woman with recurrent high-grade endometrial stromal sarcoma presented with left hypochondralgia.
  • She had undergone total hysterectomy and bilateral salpingo-oophorectomy for the disease over the past six months, and preferred not to receive additional treatment.
  • The following regimen of chemotherapy was given: each course consisted of ifosfamide (1,000 mg/m²) on days 1-5, adriamycin (60 mg/m²) on day 1, and cisplatin (15 mg/m²) on days 1-5.
  • After 4 courses of the chemotherapy, the intraabdominal mass and multiple pulmonary nodules were reduced 45.
  • This case suggests that IAP might be effective chemotherapy for patients with high-grade endometrial stromal sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Endometrial Neoplasms / drug therapy. Ifosfamide / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / radiography. Abdominal Neoplasms / secondary. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Middle Aged. Recurrence. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20948274.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


6. Kusaka M, Mikuni M, Nishiya M: A case of high-grade endometrial stromal sarcoma arising from endometriosis in the cul-de-sac. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):895-9
MedlinePlus Health Information. consumer health - Endometriosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of high-grade endometrial stromal sarcoma arising from endometriosis in the cul-de-sac.
  • This report describes a rare case of high-grade endometrial stromal sarcoma (ESS) arising from pathologically confirmed endometriosis in the cul-de-sac.
  • Magnetic resonance imaging and colon biopsy suggested endometriotic nodule of the cul-de-sac.
  • The tumor size was reduced with hormonal therapy, and the residual tumor was excised, resulting in the pathologic diagnosis of endometriosis.
  • Tumor extraction was performed, and the histopathologic diagnosis was high-grade ESS.
  • Neither hormonal therapy nor chemotherapy was effective, and the patient died 6 months postoperatively.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Endometrial Neoplasms / pathology. Endometriosis / pathology. Sarcoma, Endometrial Stromal / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Disease Progression. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • Genetic Alliance. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681780.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Sesti F, Patrizi L, Ermini B, Palmieri G, Orlandi A, Piccione E: High-grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer. Gynecol Obstet Invest; 2005;60(2):117-20
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer.
  • A case of high-grade endometrial stromal sarcoma, confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant tamoxifen.
  • Based on the findings, a high-grade endometrial stromal sarcoma was diagnosed.
  • Pathological examination on multiple uterine sections showed the absence of residual tumor cells in the uterus.
  • In deciding if tamoxifen therapy is warranted, all potentially life-threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or uterine sarcoma.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Neoplasms, Second Primary / chemically induced. Sarcoma, Endometrial Stromal / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced


8. Engin H: High-grade endometrial stromal sarcoma following tamoxifen treatment. Gynecol Oncol; 2008 Jan;108(1):253-4
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade endometrial stromal sarcoma following tamoxifen treatment.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Endometrial Neoplasms / chemically induced. Sarcoma, Endometrial Stromal / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / surgery. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17928038.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


9. Szlosarek PW, Lofts FJ, Pettengell R, Carter P, Young M, Harmer C: Effective treatment of a patient with a high-grade endometrial stromal sarcoma with an accelerated regimen of carboplatin and paclitaxel. Anticancer Drugs; 2000 Apr;11(4):275-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of a patient with a high-grade endometrial stromal sarcoma with an accelerated regimen of carboplatin and paclitaxel.
  • The rarity of endometrial stromal sarcoma (ESS) and its poor response to treatment provides fertile ground for investigational therapies.
  • A patient with a recent history of treated tuberculosis of the lung represented with infertility and acute abdominal pain from suspected fibroids, and underwent a laparotomy with a diagnosis of a high-grade ESS.
  • A novel therapeutic approach using a regimen of carboplatin and paclitaxel with the reinfusion of filgrastim-mobilized peripheral blood progenitor cells is described.
  • A partial response was observed following six cycles of chemotherapy.
  • Grade IV thrombocytopenia occurred after the last cycle, with recovery prior to pelvic radiotherapy.
  • High-grade ESS is responsive to combination chemotherapy with paclitaxel and carboplatin, and requires further evaluation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Sarcoma, Endometrial Stromal / drug therapy
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Carboplatin / adverse effects. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Transplantation. Humans. Infusions, Intravenous. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Recombinant Proteins. Thrombocytopenia / chemically induced. Tomography, X-Ray Computed. Transplantation Conditioning. Tuberculosis, Pulmonary / complications

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10898543.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


10. Salvatierra A, Tarrats A, Gomez C, Sastre JM, Balaña C: A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate. Gynecol Oncol; 2006 Jun;101(3):545-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.
  • BACKGROUND: High-grade endometrial stromal sarcoma (HGES) is an aggressive disease with dismal prognosis.
  • Surgery is the standard treatment, and radiotherapy seems to reduce local relapse.
  • No other treatment has proved to be useful in the case of non-resectable diseases.
  • CASE: A 41-year-old woman suffering HGES, with positive staining for CD117 (c-kit) and large abdominal and retroperitoneal mass progressing after chemotherapy, was treated with Imatinib Mesylate.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / biosynthesis. Pyrimidines / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / metabolism. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / metabolism

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16487996.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


11. Bodner K, Bodner-Adler B, Obermair A, Windbichler G, Petru E, Mayerhofer S, Czerwenka K, Leodolter S, Kainz C, Mayerhofer K: Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol Oncol; 2001 May;81(2):160-5
Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients.
  • OBJECTIVE: The aim of this study was to evaluate the behavior of endometrial stromal sarcomas (ESS) in relation to their clinical and pathologic features and to identify possible prognostic factors.
  • Endometrial stromal sarcoma is characterized by proliferations composed of cells with endometrial stromal cell differentiation.
  • A breakpoint of 10 mitoses per 10 high-power fields was used in the statistical analysis to distinguish between low-grade and high-grade endometrial stromal sarcoma and to evaluate the prognostic value of mitotic count in patients with ESS.
  • RESULTS: The median follow-up time was 72 months (range 34-110).
  • Adjuvant therapy was administered to 25 patients; among those, 20 patients received postoperative radiotherapy and 5 patients received chemotherapy.
  • Ten of the irradiated patients and 3 patients undergoing chemotherapy developed disease recurrence.
  • Concerning the response rate to adjuvant chemotherapy, 1 patient showed a complete response, 1 patient a partial response, 1 patient stable disease, and 2 patients progressive disease.
  • Altogether, 14 patients developed recurrent disease with a median disease-free survival of 11 months (range 5-60).
  • A univariate model revealed that early tumor stage (P < 0.0007), low myometrial invasion (P < 0.008), and low mitotic count (P < 0.005) were associated with a lengthened overall survival in patients with endometrial stromal sarcoma.
  • Age and adjuvant therapy did not influence overall survival of patients with ESS.
  • CONCLUSION: Early tumor stage, low myometrial invasion, and low mitotic count are associated with a lengthened overall survival in patients with ESS.
  • [MeSH-major] Endometrial Neoplasms / pathology. Sarcoma, Endometrial Stromal / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Neoplasm Recurrence, Local / pathology. Ovariectomy. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Salpingostomy. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11330943.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


12. Amant F, Woestenborghs H, Vandenbroucke V, Berteloot P, Neven P, Moerman P, Vergote I: Transition of endometrial stromal sarcoma into high-grade sarcoma. Gynecol Oncol; 2006 Dec;103(3):1137-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transition of endometrial stromal sarcoma into high-grade sarcoma.
  • BACKGROUND: Endometrial stromal sarcoma typically is of low grade and hormone-sensitive.
  • Although these characteristics result in an indolent behavior, little data are available on the evolution over time.
  • CASE: We report on two cases where microscopic and immunohistochemic assessment of the tumor on several occasions during 8 and 25 years of follow up enabled us to document a transition of a low-grade into a high-grade malignancy.
  • Since this transition was related to clinical loss of hormone sensitivity, the therapeutic approach consisting of hormonal treatment in combination with repetitive surgery was switched to chemotherapy only.
  • CONCLUSION: These long-term follow up data provide insight in endometrial stromal sarcoma tumor biology and highlight the importance of sampling recurrent tumors to estimate biologic behavior in order to tailor subsequent treatment.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Sarcoma, Endometrial Stromal / diagnosis
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Stromal Cells

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2007 Apr;105(1):277-8; author reply 278-9 [17306344.001]
  • (PMID = 16919712.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Amin C, Hemphill B, Sittisomwong T, Malpica A, Hunt W, Verschraegen C: Characteristics of patients with endometrial stromal sarcoma. J Clin Oncol; 2004 Jul 15;22(14_suppl):5145

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of patients with endometrial stromal sarcoma.
  • : 5145 Background: Endometrial stromal sarcoma (ESS) is by definition a low grade sarcoma, accounting for less than 1% of all tumor malignancies.
  • By comparison, the prevalence of endometrial cancer is 700 per million women.
  • Because of its rarity, the natural history of the disease and the optimal therapy have not been well established.
  • METHODS: After IRB approval, the charts of 78 patients diagnosed for the first time with ESS and treated at the University of Texas MDACC were reviewed, with emphasis on patient demographics, therapies, recurrence, and survival.
  • Patients with stromal nodule, high grade ESS (undifferentiated sarcoma), or other sarcomas were excluded.
  • Endometrial FIGO stage was I in 52%, II in 6%, III in 30%, and IV in 12%.
  • The primary site was uterus in 87% and extra-uterine in 13%.
  • The median age of onset is younger than the one of endometrial cancer, but interestingly about 75% are postmenopausal at diagnosis.
  • Various treatments including hormonal therapy, chemotherapy, radiation therapy, and hysterectomy with oophorectomy have been used, and we plan to study their impact on this disease, to present at the annual meeting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016810.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Lim MC, Lee S, Seo SS: Megestrol acetate therapy for advanced low-grade endometrial stromal sarcoma. Onkologie; 2010;33(5):260-2
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Megestrol acetate therapy for advanced low-grade endometrial stromal sarcoma.
  • BACKGROUND: Pulmonary metastases as an initial presentation of primary uterine low-grade endometrial stromal sarcoma (LGESS) are extremely rare.
  • Optimal treatment for such LGESS has not been established.
  • Chest computed tomography (CT) revealed 11 pulmonary metastases measuring up to 2.8 cm.
  • A uterine mass was detected during the workup and was diagnosed as LGESS by fine needle aspiration.
  • She was then given high-dose megestrol acetate (800 mg/day) for 4 months followed by 200 mg/day for 20 months.
  • The pulmonary metastases of LGESS began to regress with megestrol acetate treatment and almost completely disappeared 17 months after surgery.
  • At this unexpected and satisfactory response to hormonal treatment, the remaining left ovary was also surgically removed.
  • Since the surgery, the patient has been alive without symptomatic pulmonary metastases over 5 years on intermittent treatment of 200 mg megestrol acetate.
  • CONCLUSION: Megestrol acetate could be suitable as the first-line hormonal treatment for pulmonary metastases from LGESS.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Megestrol Acetate / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Sarcoma, Endometrial Stromal / secondary
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Drug Administration Schedule. Fallopian Tubes / surgery. Female. Humans. Neoplasm Staging. Omentum / surgery. Ovariectomy. Palliative Care

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20502061.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


15. Reich O, Regauer S: Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol; 2007 Jul;19(4):347-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormonal therapy of endometrial stromal sarcoma.
  • PURPOSE OF REVIEW: Low-grade endometrial stromal sarcomas are steroid receptor positive tumors with slow tumor progression and high recurrence rates, which lack established treatment protocols.
  • We present an update on hormonal therapy options.
  • RECENT FINDINGS: In the past, hormonal therapy consisted of progestins for advanced/recurrent/metastatic low-grade endometrial stromal sarcomas.
  • Aromatase inhibitors and gonadotropin-releasing hormone analogues have become new effective alternatives for first and second line treatment.
  • The high recurrence rates after short disease free intervals in low-grade endometrial stromal sarcoma patients were partly due to inadvertent growth stimulation during estrogen-containing hormone replacement therapy and tamoxifen treatment, which - according to current knowledge - are contraindicated.
  • Recently, hormonal therapy has been introduced for the prevention of recurrences.
  • Aromatase inhibitors are becoming the treatment of choice, since progestins are poorly tolerated due to side effects.
  • The effective duration of preventive hormonal therapy is still undetermined.
  • SUMMARY: Hormonal therapy with progestins, aromatase inhibitors and gonadotropin-releasing hormone analogues has become an effective treatment alternative to radiation and chemotherapy for low-grade endometrial stromal sarcoma patients.
  • Preventive hormonal therapy is of particular interest in the setting of concomitant endometriosis.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Endometrial Neoplasms / drug therapy. Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropin-Releasing Hormone / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy
  • [MeSH-minor] Aromatase Inhibitors / therapeutic use. Female. Goserelin. Humans. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOSERELIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17545798.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0F65R8P09N / Goserelin; 33515-09-2 / Gonadotropin-Releasing Hormone
  • [Number-of-references] 50
  •  go-up   go-down


16. Leunen M, Breugelmans M, De Sutter P, Bourgain C, Amy JJ: Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol; 2004 Dec;95(3):769-71
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole.
  • BACKGROUND: Low-grade endometrial stromal sarcoma is an indolent steroid responsive tumor.
  • Successful hormonal treatment, most commonly with megestrol acetate, has been reported.
  • After transvaginal trough-cut biopsy of the mass, the diagnosis of low-grade endometrial stromal sarcoma with a high expression of alpha-estrogen receptor was made.
  • The patient was treated with letrozole only with a spectacular response.
  • CONCLUSION: To the best of our knowledge, this is the first case for which letrozole was used on long-term basis as first-line hormonal treatment for a recurrent low-grade stromal sarcoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Aromatase Inhibitors / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Nitriles / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Triazoles / therapeutic use

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2005 Jul;98(1):173-4; author reply 174-5 [15963815.001]
  • (PMID = 15582003.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down


17. Lenhard SM, Untch M, Himsl I, Ditsch N, Bittmann I, Friese K, Bauerfeind I: The high-grade endometrial sarcoma: a rare entity. Arch Gynecol Obstet; 2006 Apr;274(1):56-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The high-grade endometrial sarcoma: a rare entity.
  • INTRODUCTION: With an estimated incidence of one to two per one million women, the endometrial stromal sarcoma (ESS) is a rare disease.
  • It is subclassified into a high-grade and a prognostically better low-grade type.
  • Evidence-based data for a standardized therapy is lacking.
  • A fractioned curettage yielded a differential diagnosis of malignant muellerian mixed tumor or a non-differentiated endometrial sarcoma.
  • For completion of the operative treatment, laparotomy with hysterectomy, adnexectomy, and pelvine lymphonodectomy were performed.
  • The final histological report described a 7 cm non-differentiated endometrial sarcoma with infiltration of the left ovary and 25 tumor-free lymph nodes.
  • DISCUSSION: Standard therapy for resectable sarcoma is abdominal hysterectomy and bilateral adnexectomy.
  • So far, there is little data from studies reporting radio- or chemotherapy treatment of small patient numbers in an adjuvant setting.
  • Due to missing clinical data, it remains a multidisciplinary therapeutic challenge requiring individual decisions.
  • To receive more information on this rare disease, treatment should be performed according to international protocols.
  • [MeSH-major] Endometrial Neoplasms / pathology. Sarcoma, Endometrial Stromal / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Hysterectomy. Metrorrhagia / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16311750.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Dahhan T, Fons G, Buist MR, Ten Kate FJ, van der Velden J: The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study. Eur J Obstet Gynecol Reprod Biol; 2009 May;144(1):80-4
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study.
  • OBJECTIVE: Low-grade endometrial stromal sarcoma (EES) is a rare tumour with a high recurrence rate but a very good prognosis.
  • Responses to hormonal treatment of these recurrences have been published in case reports.
  • The aim of this study was to determine the objective response rate and response duration of hormonal treatment for recurrent or residual low-grade ESS in a consecutive series of patients.
  • The following data were collected: age, date of primary diagnosis, type of primary treatment, the presence and localization of residual or recurrent disease, type of treatment, response, duration of response and survival.
  • RESULTS: After hormonal treatment 9 (82%) patients showed an objective response (4 complete response; 5 partial response), one showed stable disease (26+ months) and one progressive disease.
  • CONCLUSION: Hormonal treatment for measurable residual or recurrent low-grade ESS has a high response rate and should be considered as the treatment of choice for patients in which recurrent disease cannot easily be resected.
  • [MeSH-major] Aromatase Inhibitors / therapeutic use. Endometrial Neoplasms / drug therapy. Megestrol Acetate / therapeutic use. Nitriles / therapeutic use. Progestins / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Triazoles / therapeutic use
  • [MeSH-minor] Adult. Aged, 80 and over. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Hysterectomy. Middle Aged. Retrospective Studies. Secondary Prevention. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269732.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Progestins; 0 / Triazoles; 7LKK855W8I / letrozole; TJ2M0FR8ES / Megestrol Acetate
  •  go-up   go-down


19. Li N, Wu LY, Zhang HT, An JS, Li XG, Ma SK: [Clinical review of 97 patients with endometrial stromal sarcoma]. Zhonghua Fu Chan Ke Za Zhi; 2008 Feb;43(2):115-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical review of 97 patients with endometrial stromal sarcoma].
  • OBJECTIVE: To review the survival outcomes in patients with endometrial stromal sarcoma (ESS) in Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, and to discuss prognostic factors and the role of post-operative adjuvant radiotherapy and chemotherapy.
  • Among 97 patients, 69 had low-grade ESS (LGESS), 16 had high-grade ESS (HGESS) and 12 had unclear grade.
  • The median follow-up time was 62 months (5 - 277 months).
  • The median time-to-recurrence (TTR) was 27 months.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Sarcoma, Endometrial Stromal / pathology. Sarcoma, Endometrial Stromal / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Ovariectomy. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18683750.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Somoye G, Lawton H, Havenga S: Endometrial stromal sarcoma: experience from a district hospital and literature review. Eur J Gynaecol Oncol; 2009;30(6):664-7
Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial stromal sarcoma: experience from a district hospital and literature review.
  • PURPOSE: Endometrial stromal sarcoma (ESS) is a rare malignancy of the uterus.
  • RESULTS: There were seven cases identified over this time period highlighting the rarity of ESS.
  • Most cases were low-grade ESS and diagnosed retrospectively following surgery for presumed benign pathology.
  • Cases with high-grade ESS and advanced stage low-grade ESS received adjuvant therapy.
  • CONCLUSION: The primary treatment of ESS is surgery.
  • The role of adjuvant therapy remains debatable, but generally involves radiotherapy, chemotherapy and hormonal therapy Optimal treatment protocols may be achieved by the conduct of randomised controlled clinical trials.
  • [MeSH-major] Endometrial Neoplasms / pathology. Hospitals, District. Sarcoma, Endometrial Stromal / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Female. Great Britain. Humans. Lymph Node Excision. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20099500.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  • [Number-of-references] 28
  •  go-up   go-down


21. Geller MA, Argenta P, Bradley W, Dusenbery KE, Brooker D, Downs LS Jr, Judson PL, Carson LF, Boente MP: Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression. Gynecol Oncol; 2004 Dec;95(3):632-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression.
  • INTRODUCTION: Endometrial stromal sarcomas (ESS) are a rare gynecologic malignancy.
  • The optimal management of this cancer remains unclear, although previous reports have failed to demonstrate a clear benefit to adjuvant chemotherapy or radiation.
  • With the successful application of directed biological therapy in other sarcomas, a review of the behavior and biology of this disease is warranted.
  • OBJECTIVES: To review outcomes and patterns of failure in patients with endometrial stromal sarcoma diagnosed over 31 years at our institution and the relationship to protooncogene c-kit expression.
  • MATERIALS AND METHODS: Hospital records and pathology were reviewed for 28 patients with endometrial stromal sarcomas [19 low-grade (LGESS) and 9 high-grade (HGESS)] treated between 1972 and 2003.
  • Archival tissue samples from 16 patients were available and stained with CD 117 (c-kit) antibody (1:25 dilution).
  • Although hard to assess, due to population heterogeneity and small numbers, adjuvant chemotherapy and radiation appear to be of limited benefit.
  • Expression of c-kit was common, especially in high-grade lesions and may represent a potential therapeutic target.
  • [MeSH-major] Endometrial Neoplasms / metabolism. Endometrial Neoplasms / therapy. Neoplasm Recurrence, Local / metabolism. Proto-Oncogene Proteins c-kit / biosynthesis. Sarcoma, Endometrial Stromal / metabolism. Sarcoma, Endometrial Stromal / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Hysterectomy. Lymph Node Excision. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15581975.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1P30 CA 77598-06
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


22. Al Wakiel H, Ragheb AM, Varghese A, Juzeer A, Vashista S, Albasmy A: Uterine sarcoma: 14 years experience in KCCC. Gulf J Oncolog; 2008 Jul;(4):45-51
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine sarcoma: 14 years experience in KCCC.
  • AIM OF THE WORK: To asses the profile, pattern of failure and survival for patients with uterine sarcoma seen in KCCC.
  • MATERIAL AND METHODS: A total of 23 records for patients with uterine sarcoma attending KCCC between July 1993 to May 2007 were available for review.
  • The medical records were assessed for the profile of the disease, histological types, types of treatment, pattern of failure and survival.
  • The majority of cases 15/23 (65.2%) were endometrial stromal sarcoma, 4/23 (17.4%) had leiomyosarcoma and 4/23 (17.4%) had carcinosarcoma.
  • Five patients received palliative chemotherapy.
  • High tumor grade was seen in 12/23 (52.2%) of patients.
  • Patients with high grade tumors had a 5 year- DFS of 27% versus 100% for those with low grade tumors.
  • CONCLUSION: Stage and grade are important predictors of survival.
  • [MeSH-major] Sarcoma / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Hysterectomy. Kaplan-Meier Estimate. Kuwait. Middle Aged. Neoplasm Staging. Radiotherapy

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20084775.001).
  • [ISSN] 2078-2101
  • [Journal-full-title] The Gulf journal of oncology
  • [ISO-abbreviation] Gulf J Oncolog
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Kuwait
  • [Number-of-references] 13
  •  go-up   go-down


23. Numa F, Umayahara K, Ogata H, Nawata S, Sakaguchi Y, Emoto T, Kawasaki K, Hirakawa H, Sase M, Oga A, Kato H: De novo uterine sarcoma with good response to neo-adjuvant chemotherapy. Int J Gynecol Cancer; 2003 May-Jun;13(3):364-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] De novo uterine sarcoma with good response to neo-adjuvant chemotherapy.
  • We report here the extremely rare case of a 28-year-old woman with advanced stage uterine sarcoma arising soon after a cesarean section.
  • At the time of the procedure, there were no abnormal findings such as leiomyoma of the uterus in the abdominal cavity.
  • On the basis of a diagnosis of malignant tumor of gynecological origin, exploratory laparotomy was performed, and through biopsy, the tumor was found to be advanced undifferentiated uterine sarcoma.
  • She exhibited a good response to neoadjuvant chemotherapy consisting of cisplatin, epirubicin, and dimethyltriazenoimidazole carboxamide (DTIC) every 28 days, which was successfully followed by a hysterectomy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hysterectomy / methods. Sarcoma / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Dacarbazine / administration & dosage. Epirubicin / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Neoadjuvant Therapy. Treatment Outcome. Ultrasonography, Doppler, Color

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12801270.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 7GR28W0FJI / Dacarbazine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


24. Mitsuhashi T, Nakayama M, Sakurai S, Fujimura M, Shimizu Y, Ban S, Ogawa F, Hirose T, Ishihara O, Shimizu M: KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate. Ann Diagn Pathol; 2007 Feb;11(1):49-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate.
  • Undifferentiated endometrial sarcoma (UES) is a high-grade sarcoma that lacks specific differentiation.
  • A 61-year-old woman presented with a pelvic mass, which rapidly increased in size over the course of 3 months.
  • The mass in the hysterectomy specimen consisted of pleomorphic cells that did not show any endometrial stromal or smooth muscle differentiations; thus, the diagnosis of UES was made.
  • Multiple regional recurrences around the urinary bladder were noted after 5 months, and treatment with imatinib mesylate was started, based on the provisional interpretation of KIT immunoreactivity on a biopsy specimen of the recurrent tumor.
  • Two weeks later, the tumor shrunk significantly, as evaluated by computed tomography.
  • However, they became enlarged under the therapy after 3 months since imatinib was first started.
  • The amplified EGFR in UES has not been reported previously, and further studies are necessary to consider the possibility of EGFR-targeted therapy in such sarcomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / genetics. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Receptor, Epidermal Growth Factor / genetics. Sarcoma / drug therapy. Sarcoma / genetics

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17240308.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / DNA, Neoplasm; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


25. Gadducci A, Cosio S, Romanini A, Genazzani AR: The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol; 2008 Feb;65(2):129-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of patients with uterine sarcoma: a debated clinical challenge.
  • Uterine sarcomas include a heterogeneous group of rare tumours that usually have an aggressive clinical behaviour and a poor prognosis.
  • Total abdominal hysterectomy and bilateral salpingo-oophorectomy represents the standard surgical treatment.
  • Pelvic and/or para-aortic lymphadenectomy is indicated for carcinosarcoma, but not for leiomyosarcoma and undifferentiated endometrial sarcoma.
  • Some recent data on low numbers of patients with low-grade endometrial stromal sarcoma appear to show an incidence of nodal involvement higher than previously expected, thus suggesting a role for lymphadenectomy in this malignancy.
  • Postoperative treatment of uterine sarcomas has been long debated.
  • There is little evidence in the literature supporting the use of adjuvant chemotherapy in any gynaecological sarcomas except for carcinosarcomas.
  • However, uterine sarcomas have a high tendency to develop distant recurrences, and recent data on adjuvant chemotherapy in soft tissue sarcomas are promising.
  • As for the drugs to be used, it is worth noting that in a Swiss study, the combination of ifosfamide (IFO) and doxorubicin (DOX) obtained similar response rates in advanced gynaecological sarcomas and in advanced soft tissue sarcomas of other sites.
  • In our decision-making scheme for early-stage disease, patients with leiomyosarcoma or undifferentiated endometrial sarcoma should receive adjuvant doxorubicin/epidoxorubicin (EPIDX)+ifosfamide, and those with carcinosarcoma should be treated with adjuvant cisplatin (CDDP)-based chemotherapy.
  • The same drug regimens are used for the treatment of advanced disease.
  • Sequential pelvic radiotherapy following chemotherapy could be delivered to selected cases.
  • Recurrent disease often requires the integration of different therapeutic modalities, but no curative option is currently available with the possible exception of surgery for lung metastases and hormone therapy with or without debulking surgery for recurrent low-grade endometrial stromal sarcoma.
  • Patients should be encouraged to enter clinical trials designed to identify new active drugs for these malignancies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Neoadjuvant Therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706430.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 177
  •  go-up   go-down


26. Amant F, Coosemans A, Renard V, Everaert E, Vergote I: Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature. Int J Gynecol Cancer; 2009 Feb;19(2):245-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature.
  • The clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and undifferentiated uterine sarcoma in patients previously treated with chemotherapy is investigated.
  • Pooling the treatment outcomes with literature data, a response in 5 (38%) of 13 patients and a clinical benefit in 7 (54%) of 13 patients for all high-grade uterine sarcomas is calculated.
  • When only uterine leiomyosarcomas are concerned, response rate is 5 (45%) of 11 patients with a clinical benefit in 7 (64%) of 11 patients.
  • These results on the use of ET-743 in uterine sarcoma patients support the conductance of larger trials.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Dioxoles / administration & dosage. Sarcoma / drug therapy. Tetrahydroisoquinolines / administration & dosage. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19396002.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin
  • [Number-of-references] 13
  •  go-up   go-down


27. Hensley ML: Uterine/female genital sarcomas. Curr Treat Options Oncol; 2000 Jun;1(2):161-8
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine/female genital sarcomas.
  • Choosing the best management of uterine and vulvo-vaginal sarcomas depends on careful histologic review of the pathologic specimen.
  • Prognosis and treatment vary greatly depending on specific histology, grade, and tumor stage.
  • Adjuvant radiation decreases local recurrence rates for uterine sarcomas, but has not been clearly shown to improve overall survival.
  • It is frequently used as adjuvant therapy for resected high-grade or margin-positive vulvo-vaginal sarcomas, and for endometrial stromal sarcomas.
  • Adjuvant chemotherapy has not been demonstrated to improve survival in vulvo-vaginal sarcomas, with the exception of vulvo-vaginal rhabdomyosarcomas, nor has it been demonstrated to improve survival in uterine sarcomas.
  • Chemotherapy may be used for recurrent or persistent disease.
  • The choice of agent depends on the histologic type of sarcoma.
  • [MeSH-major] Sarcoma / therapy. Uterine Neoplasms / therapy. Vaginal Neoplasms / therapy. Vulvar Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Female. Humans. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1986 Mar;67(3):417-24 [3945454.001]
  • [Cites] Gynecol Oncol. 1993 Jul;50(1):105-9 [8349151.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Am J Obstet Gynecol. 1979 Jul 1;134(5):557-64 [453295.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [8381710.001]
  • [Cites] Cancer. 1983 Aug 15;52(4):626-32 [6344983.001]
  • [Cites] Obstet Gynecol. 1985 May;65(5):699-704 [2984620.001]
  • [Cites] Cancer. 1984 Jan 15;53(2):311-6 [6197155.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(1):1-19 [2152890.001]
  • [Cites] Cancer Treat Rep. 1986 Feb;70(2):271-4 [3948191.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1962-6 [1941054.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2487-92 [2684386.001]
  • [Cites] Am J Obstet Gynecol. 1992 Feb;166(2):556-9 [1536229.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):35-9 [2354406.001]
  • [Cites] Obstet Gynecol. 1989 Jan;73(1):75-8 [2462203.001]
  • [Cites] Cancer. 1986 Nov 1;58(9):2003-7 [3756818.001]
  • [Cites] Obstet Gynecol. 1984 Apr;63(4):550-6 [6322081.001]
  • [Cites] Am J Obstet Gynecol. 1990 Apr;162(4):968-74; discussion 974-6 [2327466.001]
  • [Cites] Cancer. 1987 Apr 1;59(7):1264-7 [3815302.001]
  • [Cites] Am J Obstet Gynecol. 1987 Mar;156(3):660-2 [3826216.001]
  • [Cites] Radiother Oncol. 1990 Feb;17(2):123-32 [2157241.001]
  • [Cites] J Clin Oncol. 1990 Nov;8(11):1847-53 [2230871.001]
  • [Cites] Obstet Gynecol. 1984 Aug;64(2):173-8 [6738952.001]
  • [Cites] Gynecol Oncol. 1985 Mar;20(3):281-9 [3838290.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3333-55 [10506637.001]
  • [Cites] Hum Pathol. 1990 Feb;21(2):223-7 [2307449.001]
  • [Cites] Gynecol Oncol. 1999 Jun;73(3):389-95 [10366465.001]
  • [Cites] Obstet Gynecol. 1973 Oct;42(4):522-6 [4742656.001]
  • [Cites] J Natl Cancer Inst. 1986 Mar;76(3):399-402 [3456457.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):618-21 [3559652.001]
  • [Cites] Gynecol Oncol. 1992 May;45(2):202-5 [1592288.001]
  • [Cites] Obstet Gynecol. 1986 Nov;68(5):709-14 [3763088.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1736-44 [10561210.001]
  • [Cites] Obstet Gynecol. 1985 Aug;66(2):262-6 [3839576.001]
  • [Cites] Obstet Gynecol. 1988 Jun;71(6 Pt 1):845-50 [2453004.001]
  • [Cites] Am J Obstet Gynecol. 1989 Aug;161(2):309-12 [2548382.001]
  • [Cites] Obstet Gynecol. 1979 Feb;53(2):213-7 [418977.001]
  • [Cites] Cancer. 1985 Apr 15;55(8):1648-53 [3884128.001]
  • [Cites] J Natl Cancer Inst. 1988 Apr 20;80(4):233-40 [3280809.001]
  • [Cites] Gynecol Oncol. 1999 Feb;72(2):232-7 [10021306.001]
  • (PMID = 12057054.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 44
  •  go-up   go-down


28. Gadducci A, Cosio S, Genazzani AR: Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. Curr Opin Investig Drugs; 2004 Oct;5(10):1031-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body.
  • The new anti-estrogens, including the selective estrogen receptor modulators (e.g., toremifene, droloxifene, idoxifene, raloxifene and arzoxifene), the selective estrogen receptor downregulators (e.g., fulvestrant), and the new steroidal (e.g., exemestane) and non-steroidal (anastrozole and letrozole) aromatase inhibitors have been investigated in the treatment of breast cancer and hormonally sensitive tumors of the uterine body.
  • In postmenopausal women, anastrozole, letrozole and exemestane appear to have superior efficacy and an improved toxicity profile than tamoxifen, and fulvestrant seems to be at least as effective as anastrozole in patients in whom tumors have progressed after prior endocrine treatment.
  • Preliminary data showed a high response rate and a favorable toxicity profile for arzoxifene in endometrial cancer, whereas letrozole could represent a new interesting therapeutic tool for endometrial cancer as well as for low-grade endometrial stromal sarcoma.
  • [MeSH-major] Aromatase Inhibitors / therapeutic use. Breast Neoplasms / drug therapy. Estrogen Antagonists / therapeutic use. Neoplasms, Hormone-Dependent / drug therapy. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Clinical Trials as Topic. Female. Humans

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15535424.001).
  • [ISSN] 1472-4472
  • [Journal-full-title] Current opinion in investigational drugs (London, England : 2000)
  • [ISO-abbreviation] Curr Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Estrogen Antagonists
  • [Number-of-references] 161
  •  go-up   go-down






Advertisement